000281435 001__ 281435
000281435 005__ 20251102002035.0
000281435 0247_ $$2doi$$a10.1002/alz.70689
000281435 0247_ $$2pmid$$apmid:40985290
000281435 0247_ $$2ISSN$$a1552-5260
000281435 0247_ $$2ISSN$$a1552-5279
000281435 0247_ $$2altmetric$$aaltmetric:181658239
000281435 037__ $$aDZNE-2025-01120
000281435 041__ $$aEnglish
000281435 082__ $$a610
000281435 1001_ $$00000-0002-6764-3866$$aMcDade, Eric M$$b0
000281435 245__ $$aThe relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology.
000281435 260__ $$aHoboken, NJ$$bWiley$$c2025
000281435 3367_ $$2DRIVER$$aarticle
000281435 3367_ $$2DataCite$$aOutput Types/Journal article
000281435 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1761730449_30627
000281435 3367_ $$2BibTeX$$aARTICLE
000281435 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281435 3367_ $$00$$2EndNote$$aJournal Article
000281435 520__ $$aTau-derived cerebrospinal fluid (CSF) biomarkers correlate with amyloid-beta (Aβ) plaques or tau tangles in Alzheimer's disease (AD). This study assessed the effects of long-term anti-Aβ antibodies on amyloid plaques, tau tangles, and CSF tau species to determine the relationships between them.A post-hoc analysis of the DIAN-TU-001 trial (NCT01760005) examined 142 participants at risk for dominantly inherited AD randomized to solanezumab (n = 50), gantenerumab (n = 52), or placebo (n = 40). High-resolution mass spectrometry quantified CSF tau species over four years.Phosphorylated tau (p-tau) species (153, 181, 217, 231) increased early in preclinical AD but were reduced with gantenerumab-mediated Aβ plaque reduction. Nearly a decade later, MTBR-tau243 and p-tau205 increased, showing no association with Aβ reduction, aligning with tau tangle pathology progression.Initially changing soluble p-tau species track Aβ plaque reduction, while ptau205 and MTBR-243 reflect tau tangle pathology, informing different pathways of therapeutic strategies.p-tau217 and p-tau231 correlate with Aβ-PET and respond to Aβ-plaque lowering therapies. Aβ immunotherapy trials support a direct link between p-tau changes and Aβ plaques Gantenerumab reduces Aβ plaques but does not affect tau NFT-related biomarkers. Blood-based p-tau217 assays may provide a non-invasive tool to monitor Aβ therapies. MTBR-tau243 strongly correlates with tau PET and tracks NFT pathology progression. Further studies are needed to validate tau biomarkers for tracking NFT-targeting therapies.
000281435 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281435 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000281435 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281435 650_7 $$2Other$$aamyloid beta plaque reduction
000281435 650_7 $$2Other$$adominantly inherited Alzheimer's disease
000281435 650_7 $$2Other$$amicrotubule‐binding region
000281435 650_7 $$2Other$$aphosphorylated tau
000281435 650_7 $$2NLM Chemicals$$atau Proteins
000281435 650_7 $$2NLM Chemicals$$aAntibodies, Monoclonal, Humanized
000281435 650_7 $$2NLM Chemicals$$aBiomarkers
000281435 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000281435 650_7 $$04DF060P933$$2NLM Chemicals$$agantenerumab
000281435 650_7 $$05D6PWO0333$$2NLM Chemicals$$asolanezumab
000281435 650_2 $$2MeSH$$aHumans
000281435 650_2 $$2MeSH$$atau Proteins: cerebrospinal fluid
000281435 650_2 $$2MeSH$$aAlzheimer Disease: cerebrospinal fluid
000281435 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000281435 650_2 $$2MeSH$$aAlzheimer Disease: drug therapy
000281435 650_2 $$2MeSH$$aPlaque, Amyloid: pathology
000281435 650_2 $$2MeSH$$aPlaque, Amyloid: drug therapy
000281435 650_2 $$2MeSH$$aPlaque, Amyloid: cerebrospinal fluid
000281435 650_2 $$2MeSH$$aMale
000281435 650_2 $$2MeSH$$aAntibodies, Monoclonal, Humanized: therapeutic use
000281435 650_2 $$2MeSH$$aFemale
000281435 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000281435 650_2 $$2MeSH$$aAmyloid beta-Peptides
000281435 650_2 $$2MeSH$$aPhosphorylation
000281435 650_2 $$2MeSH$$aMiddle Aged
000281435 650_2 $$2MeSH$$aAged
000281435 7001_ $$aBarthélemy, Nicolas R$$b1
000281435 7001_ $$aWang, Guoqiao$$b2
000281435 7001_ $$aLi, Yan$$b3
000281435 7001_ $$aCao, Yuchen$$b4
000281435 7001_ $$aGordon, Brian$$b5
000281435 7001_ $$aBenzinger, Tammie L S$$b6
000281435 7001_ $$aClifford, David$$b7
000281435 7001_ $$aGoate, Alison M$$b8
000281435 7001_ $$aRenton, Alan E$$b9
000281435 7001_ $$aHassenstab, Jason$$b10
000281435 7001_ $$aLlibre-Guerra, Jorge J$$b11
000281435 7001_ $$aPerrin, Richard J$$b12
000281435 7001_ $$aXiong, Chengjie$$b13
000281435 7001_ $$aCruchaga, Carlos$$b14
000281435 7001_ $$aMummery, Catherine J$$b15
000281435 7001_ $$aBerman, Sarah B$$b16
000281435 7001_ $$aLah, James$$b17
000281435 7001_ $$aRoberson, Erik D$$b18
000281435 7001_ $$aVan Dyck, Christopher$$b19
000281435 7001_ $$aGauthier, Serge$$b20
000281435 7001_ $$aMasters, Colin L$$b21
000281435 7001_ $$aMasellis, Mario$$b22
000281435 7001_ $$aBittner, Tobias$$b23
000281435 7001_ $$aYaari, Roy$$b24
000281435 7001_ $$aChhatwal, Jasmeer$$b25
000281435 7001_ $$aChrem, Patricio$$b26
000281435 7001_ $$aBrooks, William$$b27
000281435 7001_ $$aSuzuki, Kazushi$$b28
000281435 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes J$$b29$$udzne
000281435 7001_ $$0P:(DE-2719)2000010$$aJucker, Mathias$$b30$$udzne
000281435 7001_ $$aRingman, John$$b31
000281435 7001_ $$aWallon, David$$b32
000281435 7001_ $$aIkeuchi, Takeshi$$b33
000281435 7001_ $$0P:(DE-HGF)0$$aLee, Jae-Hong$$b34
000281435 7001_ $$aRoh, Jee Hoon$$b35
000281435 7001_ $$aSchofield, Peter$$b36
000281435 7001_ $$aFox, Nick C$$b37
000281435 7001_ $$aRyan, Natalie S$$b38
000281435 7001_ $$0P:(DE-2719)2811820$$aVöglein, Jonathan$$b39$$udzne
000281435 7001_ $$aKarch, Celeste$$b40
000281435 7001_ $$aIbáñez, Laura$$b41
000281435 7001_ $$aDay, Gregory S$$b42
000281435 7001_ $$aSánchez-Valle, Raquel$$b43
000281435 7001_ $$aDaniels, Alisha$$b44
000281435 7001_ $$aMorris, John C$$b45
000281435 7001_ $$aSupnet-Bell, Charlene$$b46
000281435 7001_ $$aLevey, Allan I$$b47
000281435 7001_ $$00000-0002-7729-1702$$aBateman, Randall J$$b48
000281435 7001_ $$aTeam, DIAN-TU Study$$b49
000281435 7001_ $$aTeam, DIAN Obs$$b50$$eCollaboration Author
000281435 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.70689$$gVol. 21, no. 9, p. e70689$$n9$$pe70689$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000281435 8564_ $$uhttps://pub.dzne.de/record/281435/files/DZNE-2025-01120%20SUP.pdf
000281435 8564_ $$uhttps://pub.dzne.de/record/281435/files/DZNE-2025-01120.pdf$$yOpenAccess
000281435 8564_ $$uhttps://pub.dzne.de/record/281435/files/DZNE-2025-01120.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281435 8564_ $$uhttps://pub.dzne.de/record/281435/files/DZNE-2025-01120%20SUP.pdf?subformat=pdfa$$xpdfa
000281435 909CO $$ooai:pub.dzne.de:281435$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000281435 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b29$$kDZNE
000281435 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000010$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b30$$kDZNE
000281435 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811820$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b39$$kDZNE
000281435 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281435 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000281435 9141_ $$y2025
000281435 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000281435 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000281435 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000281435 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000281435 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000281435 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000281435 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000281435 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000281435 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281435 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000281435 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000281435 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000281435 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000281435 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x1
000281435 9201_ $$0I:(DE-2719)1210001$$kAG Jucker$$lCell Biology of Neurological Diseases$$x2
000281435 980__ $$ajournal
000281435 980__ $$aVDB
000281435 980__ $$aUNRESTRICTED
000281435 980__ $$aI:(DE-2719)1111015
000281435 980__ $$aI:(DE-2719)1111016
000281435 980__ $$aI:(DE-2719)1210001
000281435 9801_ $$aFullTexts